UC Davis Health researchers took a critical step in defining the possible paths for the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causing COVID-19 to get transmitted from the mother to her newborn baby. The mother to fetal transmission is known as “vertical” transmission.
In an editorial published June 5 in the American Journal of Perinatology, the researchers highlighted the importance of understanding the timing and the route of infection in maternal-fetal transmission.
“There is concern that mother’s infection during pregnancy may result in transmission to the baby,” said Dean Blumberg, UC Davis chief of pediatric infectious diseases and first author on the article. “We are pleased to have the opportunity to offer a framework to look at different possible transmission pathways.”
Mother-to-child transmission of SARS-CoV-2
To date, the spread of SARS-CoV-2 from mother to fetus has not been well-established. Yet, there are three potential mechanisms of vertical transmissions of coronavirus:
Viral transmission from mother to fetus (Intrauterine transmission): Vertical transmission may occur at any time during pregnancy. It is possible that the mother may be viremic (virus in the blood) during acute infection, and the virus may be transmitted to the fetus through the placenta. Infection at different stages of pregnancy might affect the fetus in different ways, depending on the stage of fetal development. If transmission occurs late in pregnancy, the newborn may be actively infected at the time of delivery.
The transmission from mother to baby during or directly after delivery (intrapartum transmission): It can occur if the mother or someone with close contact with the baby is actively infected with the virus in the two weeks before delivery or in the two days after birth. This transmission can be present even with an initial negative swab result of the baby’s respiratory tract in the first day after birth, since the incubation period (the interval between exposure to the virus and onset of symptoms) can be up to 14 days. The baby can show a positive swab result between the second day and the 14th day after birth, or a positive test for antibodies during the first two to three weeks of postnatal life. Intrapartum or early postnatal infection could occur through exposure of the newborn to infected maternal blood or secretions.
Superficial exposure to SARS-CoV-2 (transient viremia): It is possible that the child may transiently have a positive test for the virus after delivery without actually being infected. This exposure can happen in case the mother has active viral infection during her last two weeks before delivery or in the first two days after giving birth. If the virus gets detected in the amniotic fluid, umbilical cord blood or in the baby’s respiratory or blood sample in the first day after delivery, the baby might have subsequent negative tests and does not have an immune response that indicates infection.
“In case of the mother’s confirmed infection with SARS-CoV-2, we recommend as a minimum procedure a swab of the respiratory tract of the newborn in the first and second 24-hour periods,” said Satyan Lakshminrusimha, physician-in-chief of UC Davis Children’s Hospital. “If initial SARS-CoV-2 swab tests negative, it may be repeated if the baby shows symptoms. There may be a role for antibody testing in selected patients to diagnose past infection.”
Newborn may have contracted coronavirus in the womb
Dean A. Blumberg et al, Vertical Transmission of SARS-CoV-2: What is the Optimal Definition?, American Journal of Perinatology (2020). DOI: 10.1055/s-0040-1712457
Defining paths to possible mother to child coronavirus transmission (2020, June 23)
retrieved 24 June 2020
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022